RAD 402 is a humanized IgG1 internalized by prostate cells, binding KLK3 with high affinity Tb-161 antitumor activity driven by the dual emission of beta particles and Auger electrons Nov. 18, 2025 -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced that it has been granted Bellberry Human Research Ethics Committee (HREC

Halda to be acquired by Johnson & Johnson for $3.05 billion in cash Halda recently presented positive Phase 1/2 data for HLD-0915 in metastatic castration-resistant prostate cancer and continues rapid clinical development Additional RIPTAC™ programs in development for major solid tumor types and other serious diseases Nov. 17, 2025 -- Halda Therapeutics announced today that it has entered into a definitive agreement pursuant to which Johnson & Johnson will acquire Halda for $3.05 billion, pay

Nov. 17, 2025 -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the Company), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, today announced that it has selected Allucent, a global full-service clinical research organization (CRO), to support the Company’s final preparations and planned submission of its investigational new drug application (IND) to the FDA for a Phase 1 clinical trial of its intranasal prophylactic SPC-15 as a treatment for PTSD. The C

The Company has a global license agreement for the acute pulmonary that could pay up to $78.9 million in development, regulatory and commercial milestones plus low double digit royalties The licensed treatments include SURFAXIN®, lyophilized lucinactant and AEROSURF® (a drug and device combination) The franchise is intended to treat premature infants with respiratory distress syndrome (RDS) Windtree will communicate more information about milestone payments it may receive from its licensing part

Nov. 17, 2025 -- Angiex Inc., a developer of Nuclear-Delivered Antibody-Drug Conjugate™ (ND-ADC) therapies for solid cancers, today announced the completion of financings totaling $31 million, with participation from new and existing investors. The proceeds are being used to advance AGX101, a first-in-class TM4SF1-directed ND-ADC, through the dose-escalation portion of the Phase 1 clinical trial, which is designed to assess safety, tolerability and preliminary clinical activity. “Angiex is ver

Nov. 17, 2025 -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased to announce that it has submitted an FDA Commissioner’s national priority voucher (CNPV) application on behalf of Skinject (SKNJCT-003) evaluating Doxorubicin Microneedle Array (D-MNA) to non-invasively treat basal cell carcinoma (BCC) of the skin. The submissio

TONMYA is now available by prescription and available for pharmacy ordering nationwide TONMYA is the first FDA-approved treatment for fibromyalgia in more than 15 years TONMYA is a unique, non-opioid, once-daily bedtime analgesic that significantly reduces fibromyalgia pain and is generally well-tolerated Nov. 17, 2025 -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated, commercial biotechnology company, announced today that TONMYATM (cyclobenza

-- STENOVA trial achieves primary endpoint in 103 study participants after 12 weeks of treatment -- -- Pharmacokinetic results confirm gut-restricted profile of ontunisertib in FSCD patients -- -- Positive efficacy signals observed for several exploratory clinical endpoints -- -- Ongoing open-label extension study supports longer-term safety and tolerability profile observed to date -- November 17, 2025 – Agomab Therapeutics NV (‘Agomab’) today announced positive data from 103 participants comp

Nov. 17, 2025 -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that interim data from Cohort A of the ongoing Phase 2 open-label ADVANCED-2 trial of TARA-002 in BCG-Naïve patients with non-muscle invasive bladder cancer (NMIBC) will be featured during a poster session at the upcoming 26th Annual Meeting of the Society of Urologic Oncology (SUO) taking place from December 2, 2

-- Preclinical data with TK-6302 has shown best-in-class anti-tumor efficacy, demonstrating its potential to elicit deep and durable responses in diverse solid tumor indications with high unmet need -- Following CTA approval, Phase 1 ATLAS trial planned to begin in 2026 Nov. 17, 2025 -- T-knife Therapeutics, Inc., a biopharmaceutical company developing next-generation T cell therapies to fight cancer, today announced the filing of a Clinical Trial Application (CTA) to begin the Phase 1 ATLAS t